Sulforaphane Treatment for Autism Spectrum Disorder: A Systematic Review

Autism Spectrum Disorder (ASD) is defined as a neurodevelopmental condition characterized by social communication impairment, delayed development, social f

Greer McGuinness, Kim, Yeonsoo

PubMed · 2020 · https://doi.org/10.17179/excli2020-2487

Abstract

Autism Spectrum Disorder (ASD) is defined as a neurodevelopmental condition characterized by social communication impairment, delayed development, social function deficit, and repetitive behaviors. The Center for Disease Control reports an increase in ASD diagnosis rates every year. This systematic review evaluated the use of sulforaphane (SFN) therapy as a potential treatment option for individuals with ASD. PubMed.gov, PubMed Central, Natural Medicines, BoardVitals, Google Scholar and Medline were searched for studies measuring the effects of SFN on behavior and cognitive function. All five clinical trials included in this systematic review showed a significant positive correlation between SFN use and ASD behavior and cognitive function. The current evidence shows with minimal side effects observed, SFN appears to be a safe and effective treatment option for treating ASD.

Licence and reuse

LicenceCC-BY-4.0
May we host this PDF?Yes
May we publish a plain-language summary?Yes — this licence permits adaptations.
Commercial use permitted?Yes
Share-alike required?No

How to credit this work

Greer McGuinness; Kim, Yeonsoo (2020). Sulforaphane Treatment for Autism Spectrum Disorder: A Systematic Review. PubMed. https://doi.org/10.17179/excli2020-2487 Licensed under Creative Commons Attribution 4.0 (https://creativecommons.org/licenses/by/4.0/). Hosted by EVEC Athens (microgreens.org.gr). No changes were made to this article. Provided as-is, without warranties. EVEC Athens is not affiliated with, and this copy is not endorsed by, the authors or the publisher.

Explore this on our site

About this copy

This is a copy of the published article, hosted by EVEC Athens for free educational use under its open licence. The permanent scientific reference is the DOI above. We have not altered the file in any way. If you are an author or rights holder and want this copy removed, please use our notice and takedown procedure. We acknowledge every request within five working days, and act within ten.

Co-funded by the European Union.
This portal presents the microgreens methodology; the organisation behind it is EVEC Athens — the European Voluntary and Educational Center (evec.org.gr). Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the granting authority can be held responsible for them.

Open licence. Except where stated otherwise, the educational materials on this portal are licensed under CC BY 4.0 — free to use, adapt and share, including commercially, with credit. See the licence terms.

Accessibility. We aim for WCAG 2.1 AA and publish what does and does not yet meet it — see the accessibility statement. If anything here blocks you, tell us and we will send the material in a format that works for you.